
Supplementary Material


Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid- β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients

Supplementary Figure 1. Pre-baseline comorbidities stratified by severity and amyloid- β status.



Odds ratio with 90% CIs of comorbidities (ICD-9 codes) for Amy+ versus Amy- status in MCI and MILD cohorts. Amy-, amyloid-negative; Amy+, amyloid-positive; CI, confidence interval; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; ICD-9, International Classification of Disease 9th Revision; MCI, mild cognitive impairment; MILD, mild dementia; OR, odds ratio; PNS, peripheral nervous system.

Supplementary Figure 2. Diagnosis with AD and cognitive impairment components in MILD versus MCI and amyloid-positive versus amyloid-negative cohorts before baseline visit.



Odds ratio with 90% CIs are represented for diagnosis of AD and specific cognitive impairment components by (A) severity, and (B) amyloid-β status. AD, Alzheimer's disease; Amy-, amyloidnegative; Amy+, amyloid-positive; beh. dis., behavioral disturbances; CI, confidence interval; MCI, mild cognitive impairment; MILD, mild dementia; OR, odds ratio; w/o, without.

Note: The components listed above represent the ICD diagnoses observed in the Medicare data.

Supplementary Table. 1 List of ICD-9 codes used for Alzheimer's disease and cognitive impairment diagnosis.

ICD-9 code	ICD-9 DESCRIPTION
2900	Senile dementia, uncomplicated
29010	Presenile dementia, uncomplicated
29011	Presenile dementia with delirium
29013	Presenile dementia with depressive features
29021	Senile dementia with depressive features
2903	Senile dementia with delirium
29040	Vascular dementia, uncomplicated
29041	Vascular dementia, with delirium
29042	Vascular dementia, with delusions
29043	Vascular dementia, with depressed mood
29410	Dementia in conditions classified elsewhere without behavioral disturbance
29411	Dementia in conditions classified elsewhere with behavioral disturbance
29420	Dementia, unspecified, without behavioral disturbance
29421	Dementia, unspecified, with behavioral disturbance
2949	Unspecified persistent mental disorders due to conditions classified elsewhere
31081	Pseudobulbar affect
31089	Other specified nonpsychotic mental disorders following organic brain damage
3310	Alzheimer's disease
33111	Pick's disease
33119	Other frontotemporal dementia
3312	Senile degeneration of brain
3317	Cerebral degeneration in diseases classified elsewhere
33182	Dementia with Lewy bodies
33183	Mild cognitive impairment, so stated
33189	Other cerebral degeneration
3319	Cerebral degeneration, unspecified
34830	Encephalopathy, unspecified
4380	Late effects of cerebrovascular disease, cognitive deficits
78009	Other alteration of consciousness
78093	Memory loss
797	Senility without mention of psychosis

ICD-9, International Classification of Disease 9th Revision.

Supplementary Table 2. All-cause healthcare utilization and costs based on severity during the

pre- and post-diagnosis phases.

	Pre-diagnosis phase			Post-diagnosis phase								
Categories ^a	MCI N = 96	MILD N = 70	p	MCI N = 60	MILD N = 55	p						
Utilization PPPM, mean	Utilization PPPM, mean (SD)											
Inpatient acute episodes	0.01 (0.12)	0.01 (0.12)	0.899	0.01 (0.08)	0.02 (0.13)	0.041						
Outpatient emergency department visits	0.02 (0.17)	0.04 (0.20)	0.091	0.02 (0.16)	0.05 (0.22)	0.017						
Outpatient clinic visits	0.06 (0.29)	0.02 (0.17)	0.251	0.07 (0.28)	0.04 (0.25)	0.283						
Outpatient general practitioner visits	0.36 (0.65)	0.46 (0.80)	0.091	0.48 (0.76)	0.52 (0.77)	0.508						
Outpatient specialist visits	0.86 (1.27)	0.77 (1.33)	0.613	1.22 (1.53)	1.07 (1.27)	0.398						
Inpatient acute days	0.05 (0.53)	0.07 (0.68)	0.624	0.03 (0.46)	0.10 (0.99)	0.070						
Skilled nursing facility days	0.01 (0.40)	0.06 (1.13)	0.220	0.07 (1.16)	0.16 (1.80)	0.295						
All-cause costs PPPM in	USD, mean (S	D)										
Ambulance/transport	\$2 (31)	\$3 (35)	0.794	\$2 (35)	\$6 (57)	0.047						
Durable medical equipment	\$11 (84)	\$13 (110)	0.700	\$21 (98)	\$9 (87)	0.200						
Emergency department	\$3 (25)	\$6 (35)	0.059	\$3 (26)	\$7 (43)	0.019						
Home health	\$28 (304)	\$72 (541)	0.254	\$9 (157)	\$120 (681)	0.014						
Skilled nursing facility	\$6 (251)	\$19 (380)	0.346	\$31 (508)	\$80 (918)	0.231						
Hospice	\$0 (0)	\$0(0)		\$0 (0)	\$46 (483)	0.310						
Inpatient acute	\$129 (1420)	\$119 (1266)	0.856	\$122 (3255)	\$257 (3414)	0.314						
Inpatient non-acute	\$0 (0)	\$0 (0)		\$29 (702)	\$45 (849)	0.619						
Outpatient hospital/facility	\$81 (586)	\$118 (685)	0.233	\$142 (896)	\$128 (766)	0.700						
Professional provider (carrier) inpatient	\$23 (343)	\$18 (199)	0.585	\$8 (100)	\$27 (286)	0.045						
Professional provider (carrier) non-inpatient	\$160 (306)	\$162 (599)	0.848	\$216 (411)	\$295 (1772)	0.467						
Testing and imaging	\$62 (190)	\$65 (172)	0.765	\$89 (290)	\$82 (158)	0.628						
Part B covered drugs	\$20 (155)	\$35 (249)	0.480	\$36 (209)	\$83 (476)	0.307						
Other	\$7 (59)	\$4 (19)	0.522	\$3 (24)	\$5 (27)	0.411						
Total healthcare costs	\$532 (1926)	\$633 (2074)	0.416	\$712 (4115)	\$1191 (4700)	0.067						
9 A 1' + 1 C 1 - 1 C C	c : 1: .	. 1 1		G 11'	1 1							

^a Adjusted for length of fee-for-service history in each diagnosis phase. General linear model regression analyses were conducted adjusting for patient observation months.

MCI, mild cognitive impairment; MILD, mild dementia; PPPM, per patient per month; SD, standard deviation; USD, United States Dollar.

Bolded p-values represent significant difference between amyloid-negative (Amy-) and amyloid-positive (Amy+) cohorts (p < 0.1).

Supplementary Table 3. All-cause healthcare utilization and costs based on amyloid- β status

during the pre- and post-diagnosis phases.

	Pre-diagnosis phase			Post-diagnosis phase							
Categories ^a	Amy- N = 74	Amy + N = 92	p	Amy- N = 51	Amy + N = 64	p					
Utilization PPPM, mean (SD)											
Inpatient acute episodes	0.01 (0.12)	0.01 (0.12)	0.928	0.02 (0.14)	0.01 (0.08)	0.010					
Outpatient emergency department visits	0.03 (0.18)	0.03 (0.18)	0.677	0.04 (0.21)	0.03 (0.18)	0.309					
Outpatient clinic visits	0.06 (0.31)	0.03 (0.20)	0.170	0.05 (0.29)	0.05 (0.25)	0.977					
Outpatient general practitioner visits	0.43 (0.76)	0.37 (0.66)	0.306	0.55 (0.79)	0.46 (0.75)	0.262					
Outpatient specialist visits	0.99 (1.40)	0.71 (1.20)	0.036	1.15 (1.38)	1.14 (1.43)	0.896					
Inpatient acute days	0.05 (0.47)	0.07 (0.66)	0.419	0.11 (1.04)	0.03 (0.46)	0.046					
Skilled nursing facility days	0.01 (0.33)	0.04 (0.95)	0.267	0.20 (1.98)	0.05 (1.03)	0.081					
All-cause costs PPPM in	USD, mean (S	D)									
Ambulance/transport	\$3 (42)	\$1 (23)	0.103	\$6 (54)	\$3 (41)	0.163					
Durable medical equipment	\$11 (54)	\$12 (115)	0.952	\$27 (113)	\$7 (75)	0.022					
Emergency department	\$5 (34)	\$4 (26)	0.270	\$6 (38)	\$5 (33)	0.643					
Home health	\$21 (321)	\$61 (460)	0.210	\$124 (693)	\$19 (252)	0.022					
Skilled nursing facility	\$5 (170)	\$15 (374)	0.322	\$97 (986)	\$25 (478)	0.082					
Hospice	\$0 (0)	\$0 (0)		\$53 (519)	\$0 (0)	0.239					
Inpatient acute	\$120 (1344)	\$129 (1383)	0.866	\$283 (3637)	\$118 (3092)	0.284					
Inpatient non-acute	\$0(0)	\$0(0)		\$35 (633)	\$38 (867)	0.917					
Outpatient hospital/facility	\$101 (703)	\$89 (557)	0.681	\$178 (1157)	\$104 (478)	0.042					
Professional provider (carrier) inpatient	\$19 (248)	\$23 (332)	0.694	\$27 (293)	\$9 (123)	0.089					
Professional provider (carrier) non-inpatient	\$173 (319)	\$151 (505)	0.411	\$324 (1901)	\$204 (397)	0.259					
Testing and imaging	\$69 (156)	\$59 (203)	0.397	\$91 (222)	\$82 (244)	0.595					
Part B covered drugs	\$14 (100)	\$34 (242)	0.201	\$25 (145)	\$83 (462)	0.211					
Other	\$5 (24)	\$7 (60)	0.651	\$5 (25)	\$4 (26)	0.814					
Total healthcare costs	\$547 (1921)	\$584 (2025)	0.729	\$1281 (5007)	\$701 (3911)	0.034					

^a Adjusted for length of fee-for-service history in each diagnosis phase. General linear model regression analyses were conducted adjusting for patient observation months.

Âmy-, amyloid-negative cohort; Amy+, amyloid-positive cohort; PPPM, per patient per month; SD, standard deviation; USD, United States Dollar.

Bolded p-values represent significant difference between amyloid-negative and amyloid-positive cohorts (p<0.1).